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Edited by Judit OvadiAbstract Two phosphofructokinase (PFK) chimeras were con-
structed by exchanging the N- and C-terminal halves of the
mammalian M- and C-type isozymes, to investigate the contribu-
tion of each terminus to the catalytic site and the fructose-2,6-
P2/fructose-1,6-P2 allosteric site. The homogeneously-puriﬁed
chimeric enzymes organized into tetramers, and exhibited kinetic
properties for fructose-6-P and MgATP similar to those of the
native enzyme that furnished the N-terminal domain in each
case, whereas their fructose-2,6-P2 activatory characteristics
coincided with those of the isozyme that provided the C-terminal
half. This reﬂected the role of each domain in the formation of
the corresponding binding site. Grafting the N-terminus of
PFK-M onto the C-terminus of the fructose-1,6-P2 insensitive
PFK-C restored transduction of this signal to the catalytic site,
which signiﬁcance is also discussed.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Phosphofructokinase (PFK) is a paradigm of an allosteric
enzyme whose activity is regulated by a series of metabolites,
so that it is thought essential for the control of glycolysis in
most organisms [1–3]. Although the allosteric nature of PFK
has been established in the simple prokaryotic enzyme after
determination of its three-dimensional structure (reviewed in
[4]), our knowledge on the molecular basis of the allosteric
behavior of the more complex eukaryotic PFK is still poor.
Eukaryotic PFKs are about twice the size of the bacterial en-Abbreviations: PFK, phosphofructokinase; HmPFK and AtPFK, the
PFKs from human muscle and ascites tumor cells, respectively;
ChiPFK-MC, the chimeric PFK composed of the N-terminal half of
HmPFK-M and the C-terminal half of AtPFK-C; ChiPFK-CM, the
chimeric PFK composed of the N-terminal half of AtPFK-C and the
C-terminal half of HmPFK-M
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doi:10.1016/j.febslet.2007.05.059zyme as a result of duplication, fusion and divergence of an
ancestral prokaryotic gene originating new allosteric sites [5].
Thus, the binding site of the potent activator fructose-2,6-P2
evolved from the duplicated fructose-6-P catalytic site of the
prokaryotic enzyme in the C-terminal half, as indicated by se-
quence alignments with bacterial PFK and site-directed muta-
genesis [6–8]. Sequence conservation and the crystal structure
of the bacterial enzyme also suggest that the active site of
eukaryotic PFK is located in the N-terminal half, and that
both sites are shared in the interface between subunits [4,5].
The subsite for MgATP at the catalytic site was proposed to
be conﬁned to a single subunit [4,5]. Although some amino
acids involved in the function of several speciﬁc ligands, like
the inhibitors MgATP and citrate [7,9,10] and the activator
fructose-2,6-P2 [6–8] have been identiﬁed, the role of the N-
and C-terminal domains in the formation of the catalytic site
and the fructose bisphosphate binding site has not been exper-
imentally tested. No X-ray structure of a characteristic eukary-
otic PFK has been provided yet, other than that of the
Trypanosoma brucei enzyme in which no gene duplication took
place [11].
In mammalian cells, PFK isozymes are composed of three
types of subunits, C, M and L, which form homo- and het-
ero-tetramers and are encoded by diﬀerent genes showing tis-
sue-speciﬁc expression [12,13]. Individual regulatory
characteristics of homo-tetramers of the three isozymes have
been reported that may contribute to the distinctive glycolytic
ﬂux in particular tissues [13–15]. With respect to the M and C
isozymes, although functional diﬀerences at the fructose-6-P
catalytic site are present, such as a lower aﬃnity and a higher
cooperativity of PFK-C for this substrate [10,14–16], most
pronounced diﬀerences are established at the regulatory prop-
erties of the fructose-2,6-P2/fructose-1,6-P2 allosteric site.
Thus, PFK-C shows one order of magnitude lower aﬃnity
for fructose-2,6-P2 [10,16] and is completely insensitive to fruc-
tose-1,6-P2 [16], whereas PFK-M [17], as well as PFK-L [18],
are strongly activated by this metabolite. Interestingly, PFK-
C binds fructose-1,6-P2 with a low micromolar Kd value [16],
close to that of PFK-M [16], indicating that although both bis-
phosphates share a common (or partially overlapping) binding
site [19,20], fructose-1,6-P2 evokes a diﬀerent conformational
change, which structural route to the catalytic site is altered
in the C isozyme. Therefore, the M and C isozymes are partic-
ularly suitable to investigate the contribution of the N- and C-
termini to the characteristics of the fructose-6-P catalytic site
and the fructose bisphosphate allosteric site, by constructionblished by Elsevier B.V. All rights reserved.
3034 O.H. Martı´nez-Costa et al. / FEBS Letters 581 (2007) 3033–3038of two chimeric PFKs involving exchange of their terminal do-
mains. We have found that the aﬃnity properties of the chime-
ric enzymes for fructose-6-P and fructose-2,6-P2 resembled
those of the native isozyme that donated the N-terminal half
and the C-terminal half, respectively. Both chimeric enzymes
were activated by fructose-1,6-P2, although with a markedly
diﬀerent apparent aﬃnity, which signiﬁcance regarding the ab-
sence of this eﬀect in PFK-C is also discussed.2. Materials and methods
2.1. Materials
All chemical reagents and enzymes used in genetic assays and pro-
tein puriﬁcation were obtained from Roche Diagnostics, Amersham
Biosciences, or Sigma. Oligonucleotides were synthesized by Isogen.
Antibodies against the M subunit of rat muscle PFK and against brain
PFK (C-type) were kindly donated by Dr. G.A. Dunaway (Southern
Illinois University). Other reagents were obtained from commercial
sources and were of the best grade available.2.2. Strains, media and growth conditions
The Escherichia coli strains were DH5a and TG1 [21]. The Saccha-
romyces cerevisiae strain HD152-1D [16], carrying deletions in both
yeast PFK genes was used for the expression of wild-type HmPFK-
M and AtPFK-C and the chimeric enzymes ChiPFK-CM and
ChiPFK-MC. Standard procedures were employed for E. coli [21]
and yeast [22] manipulations.2.3. Molecular biology techniques and plasmids construction
Recombinant DNA manipulations were carried out by published
methods [21]. Chimeric genes of AtPFK-C with HmPFK-M, and N-
and C-truncated genes of AtPFK-C were constructed by PCR ampliﬁ-
cation [10], using plasmid p18TPC [16], carrying the cDNA for
AtPFK-C, as the template and the following oligonucleotide primers:
primer 1, 5 0- CCGgcatgcTTACACTGTGTGGTTGCTCTTGACAA-
TCTTCTC-3 0 and primer 2, 5 0-CCGGtctagaTGCACACAGTGG-
CCGTCATCAATGTAGGGGCACC-3 0 (introduced SphI and XbaI,
and DraIII restriction sites are in lower case and in italics, respectively;
start and stop codons in bold face). PCR using primer 1 and the 16-
mer reverse sequencing primer ampliﬁed the 5 0 region of AtPFK-C
corresponding to its N-terminus. The chimeric gene for ChiPFK-CM
was created by digesting this PCR product with XbaI and DraIII
and its simultaneous cloning with the DraIII–SphI-digested fragment
from p18HmPFK [16] into XbaI–SphI sites of the expression vector
pJJH71 under the control of the S. cerevisiae PFK2 promoter [23],
yielding plasmid pSCM. In this way, the AtPFK-C gene up to codon
for N409 was grafted in frame onto the HmPFK-M gene beginning
at the codon for H401. Primer 2 and the 17-mer universal primer were
used to amplify the 3 0 region of AtPFK-C. To create the chimeric gene
for ChiPFK-MC, the DraIII–SphI-digested PCR product and the
BamHI–DraIII fragment obtained from p18HmPFK were ligated
and cloned into BamHI–SphI sites of pJJH71, giving plasmid pSMC,
which contained the HmPFK-M gene up to the codon for V403 in
frame with the AtPFK-C gene starting at codon for A413. For the gen-
eration of the recombinant plasmids pCHA1-N and pCHA1-C, con-
taining the cDNAs for the truncated N- or C-terminal halves,
respectively, of AtPFK-C, the corresponding PCR products obtained
as above were digested with XbaI and SphI and cloned into XbaI–SphI
sites of pJJH71. Plasmid pCM010A, carrying the cDNA for E. coli pfk
gene was constructed by cloning the 1.3-kbp BamHI fragment from
pHL1 [24] into pJJH71. Sequence integrity of the plasmid constructs
was conﬁrmed by DNA sequencing. For expression of AtPFK-C
and HmPFK-M in yeast, the plasmids pCHA1 [16] and pJJH71PFK
[23] were used.2.4. Expression and puriﬁcation of recombinant enzymes
Wild-type AtPFK-C and HmPFK-M and the chimeric forms
ChiPFK-MC and ChiPFK-CM were expressed in PFK-deﬁcient S.
cerevisiae strain transformed with the corresponding pJJH71 deriva-
tive. The recombinant enzymes were puriﬁed from 1 L of yeast trans-formants grown to stationary phase in rich medium containing
glucose, by chromatographies on blue Sepharose CL-6B and DEAE-
trisacryl as described [10], except for ChiPFK-MC. This chimera was
subjected to a 5% (w/v) polyethylene glycol fractionation, and was fur-
ther puriﬁed after the DEAE-trisacryl chromatographic step by ammo-
nium sulfate precipitation at 50% saturation and FPLC size-exclusion
chromatography on a Superdex 200HR 10/30 column, as described
previously [25]. The enzymes were shown to be pure by SDS–poly-
acrylamide gel electrophoresis (SDS–PAGE) analysis (Fig. 2).
2.5. PFK activity assay
Total PFK activity was measured as described previously [16]. As-
says for kinetic studies were carried out at pH 7.0 in 50 mM Hepes,
100 mM KCl, 5 mM MgCl2, 0.15 mM NADH, 1.2 U aldolase, 10 U
triosephosphate isomerase, 1 U glycerol-3-P dehydrogenase, 2–5 ll of
the puriﬁed enzyme, and the indicated concentrations of MgATP,
eﬀector, and fructose-6-P in a ﬁnal volume of 1 ml. In all cases, the
reaction was started after a 5-min preincubation by the addition of
fructose-6-P, and was followed by measuring the absorbance change
at 340 nm at 25 C. When the eﬀect of fructose-1,6-P2 was examined,
pyruvate kinase (1 U) and lactate dehydrogenase (1 U) were used as
coupling enzymes in the presence of 0.12 mM phosphoenolpyruvate.
One unit (U) of activity is deﬁned as the amount of enzyme that cata-
lyzes the conversion of 1 lmol of substrate/min under the above con-
ditions. Kinetic data are the average of a minimum of three
measurements. Standard error did not exceed 10% of the average va-
lue. Kinetic parameters were determined by linear regression analysis
of either double-reciprocal plots or the Hill equation (r values were
above 0.95).
2.6. Other methods
Isolation of total RNA and Northern blots were carried out as de-
scribed [26], except that ﬁlter incubations were made at 42 C in the
presence of 50% formamide. SDS–PAGE on 10% gels, Coomassie Blue
staining, Western blots and immunostaining were carried out as de-
scribed [16,27]. Antibodies were used at a 1:1000 dilution. Protein con-
centration was determined by the method of Bradford [28].3. Results and discussion
3.1. Construction and expression of chimeric enzymes
To construct two chimeric PFKs in which the N- and C-ter-
minal halves of AtPFK-C and HmPFK-M were exchanged, we
took advantage of a unique DraIII restriction site located in
the middle region of the coding sequence of HmPFK-M. This
allowed digestion at a position corresponding to the end of the
73-residue peptide that connects the two terminal PFK do-
mains (S400H) [29]. Thus, ChiPFK-CM was composed of the
409 N-terminal residues from AtPFK-C and the 380 C-termi-
nal residues from HmPFK-M starting at H401, whereas
ChiPFK-MC contained the 403 N-terminal residues from
HmPFK-M and the 372 C-terminal residues from AtPFK-C
starting at A413.
As seen in Fig. 1A, both ChiPFK-CM and ChiPFK-MC
were functionally expressed in a S. cerevisiae strain lacking
the endogenous PFK genes, as yeast transformants with the
corresponding plasmids (pSCM and pSMC, respectively) com-
plemented the glucose-negative phenotype of the recipient
strain. In contrast, transformants with either plasmid
pCHA1-N or pCHA1-C containing the sequence of the N-
or the C-terminus of AtPFK-C, respectively, could not com-
plement the PFK deﬁciency under similar conditions, while
transformation with plasmid pCM010A carrying the full-
length cDNA for E. coli PFK (equivalent to about a terminal
half of the mammalian enzyme) could restore growth on the
glucose-containing medium. Nevertheless, transcription of
the cDNAs corresponding to each PFK-C-termini was ob-
Fig. 1. Growth of transformants on diﬀerent carbon sources (A) and expression analysis of chimeric enzymes and the N- and C-terminal halves of
AtPFK-C at mRNA level (B and C). (A) Three independent transformants of strain HD152-1D (MATa, pfk1::HIS3, pfk2::HIS3, ura3-52, his3-D1,
leu2-3,112, trp1-289, MAL2-8c, SUC2, GAL) with the indicated plasmids were streaked onto YNBGE, left to grow and replica-plate onto YNBD
lacking uracil. They were incubated for 4 days at 30 C. (B and C) Northern blots of total RNA were hybridized with the 32P-labeled cDNA
corresponding to either the N (B) or C (C) terminus of AtPFK-C. Total RNA was isolated from yeast transformed with the indicated plasmid and
grown on liquid YNBGE lacking uracil. Yeast carrying the vector plasmid, pJJH71, was used as control. Ten micrograms of RNA were loaded per
lane, and methylene blue staining of 25S rRNAs conﬁrms approximately equal loading of RNA in all lanes.
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ern blots from transformants with pCHA1-N and pCHA1-C,
respectively, versus the chimeric transcripts of 2.6–2.7 kb
(Fig. 1B and C). However, no proteins of the corresponding
molecular masses could be identiﬁed by either SDS–PAGE
or Western blots (data not shown), suggesting that half sub-
units of AtPFK-C are unstable because they lack the interac-tions normally made with the other half subunit in the native
enzyme.
3.2. Structural properties of chimeric enzymes
Final preparations of chimeric PFKs had speciﬁc activity
values close to those of the native enzymes (see legend to
Fig. 3) and showed each a single band in SDS–PAGE of 87
Fig. 2. SDS–PAGE of puriﬁed wild-type and chimeric forms of
HmPFK-M and AtPFK-C. One to ﬁve micrograms of puriﬁed
enzymes were loaded per lane. The positions and molecular masses
of marker proteins are indicated on the right.
Fig. 3. Dependence of the activity of wild-type and chimeric enzymes
on substrate concentration. (A) Fructose-6-P saturation curve carried
out at pH 7.2 and either 5 or 7.5 mM MgATP for wild-type enzymes
and ChiPFK-CM, and ChiPFK-MC, respectively. Activity is ex-
pressed relative to maximal activity obtained under these conditions
for each enzyme (35, 34, 21, and 28 U/mg protein for HmPFK-M,
AtPFK-C, ChiPFK-MC, and ChiPFK-CM, respectively). (B) Initial
velocity as a function of ATP concentration assayed at pH 7.0 with
2 mM fructose-6-P. s, HmPFK-M; n, AtPFK-C; d, ChiPFK-MC;
and m, ChiPFK-CM.
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indicating that they were homogeneous (Fig. 2). These values
agreed with the calculated molecular masses from the protein
sequences. The puriﬁed enzymes eluted as single peaks from
FPLC size-exclusion chromatography with a similar molecular
mass of 370 kDa for both ChiPFK-CM and ChiPFK-MC.
Thus, the chimeric enzymes are able to organize into tetramers,
like native PFKs, which showed a molecular mass of 370 kDa
for both AtPFK-C and HmPFK-M, under similar conditions.
3.3. Fructose-6-P and MgATP saturation kinetics
As shown in Fig. 3A, ChiPFKs diﬀered in their aﬃnity and
cooperativity properties for fructose-6-P, resembling those of
the native isozyme that provided de N-terminal half. Thus,
ChiPFK-CM exhibited S0.5 (3.4 mM) and nH (3.5) values for
this substrate that were very close to those of AtPFK-C
(S0.5 = 3.5 mM, nH = 3.8), whereas ChiPFK-MC showed high-
er aﬃnity (S0.5 = 1.8 mM) and some lower cooperativity
(nH = 3.1), that were more similar to the corresponding prop-
erties of HmPFK-M (S0.5 = 2.5 mM, nH = 2.9). These results
are consistent with the hypothesis that the fructose-6-P cata-
lytic site is located in the N-terminus of eukaryotic PFK. Ex-
change of the terminal domains did not modify catalysis
signiﬁcantly, as indicated by the kcat values of ChiPFK-CM
(210 s1) and ChiPFK-MC (230 s1) compared with those of
AtPFK-C (250 s1) and HmPFK-M (290 s1). This agrees
with the high sequence identity between the donating isozymes
(70% to the N-terminal half and 68% to the C-terminal half).
Chimeric enzymes exhibited MgATP saturation curves that
were strongly distinct (Fig. 3B). ChiPFK-CM showed a high
aﬃnity for this substrate, with a Km value (30 lM) closer to
that of AtPFK-C (Km = 40 lM) than to HmPFK-M (Km =
80 lM). However, the MgATP inhibition of this chimera was
more similar to that of HmPFK-M (Ki values of 2.3 and
2.1 mM, respectively) than to AtPFK-C (Ki = 0.9 mM). In
contrast, ChiPFK-MC showed a large decrease in the apparent
aﬃnity of the catalytic site for MgATP (Km = 1500 lM),approaching that of the inhibitory site, and much lower activ-
ity with increasing concentrations of the nucleotide. Saturation
kinetics for MgATP reﬂects its mixed actions on both binding
sites. Therefore, the observed decrease in enzyme eﬃciency
could be mediated by either an extensive decrease in the aﬃnity
of the catalytic site, or a marked increase in that of the inhib-
itory site. We used MgITP as a phosphoryl donor, which is not
a PFK inhibitor [30,31], to distinguish between both possibili-
ties. As seen in Fig. 4, aﬃnity of ChiPFK-MC for MgITP was
practically similar to that of HmPFK-M (Km values of 2.1 and
1.8 mM, respectively), whereas it was signiﬁcantly lower than
that of AtPFK-C (Km = 0.2 mM). We take this as an indica-
tion of no substantial change in the actual aﬃnity of the cata-
lytic site for MgATP, and favors that grafting the C-terminus
of AtPFK-C (which is more sensitive to inhibition by this
metabolite) onto the N-terminus of HmPFK-M elicited partic-
ular interactions between these diﬀerent termini, that increased
Fig. 4. Kinetic behavior of HmPFK-M, AtPFK-C and ChiPFK-MC
with respect to the nucleoside triphosphate. Assays were carried out
with various concentrations of either MgATP (open symbols) or
MgITP (closed symbols) and 2 mM fructose-6-P at pH 7.0. Inset,
AtPFK-C activity with MgITP. Fig. 5. Eﬀect of fructose-2,6-P2 (A) and fructose-1,6-P2 (B) on wild-
type and chimeric enzymes. Fructose bisphosphate activation was
performed at 2 mM fructose-6-P at pH 7.0. MgATP concentration was
ﬁxed at either 5 or 7.5 mM for wild-type isozymes and ChiPFK-CM,
and ChiPFK-MC, respectively. Activity is expressed relative to the
maximal obtained for each enzyme. s, HmPFK-M; n, AtPFK-C; d,
ChiPFK-MC; and m, ChiPFK-CM.
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that of AtPFK-C, thus reducing the eﬃciency of the catalytic
site. Together, these data are in accordance with those of fruc-
tose-6-P saturation curves supporting that the N-terminal half
contributes to the catalytic site, and suggest that the C-termi-
nal half plays an important role in the aﬃnity characteristics
of the MgATP inhibitory site. In fact, several amino acids of
the C-terminus have been found essential for the function of
this allosteric site in the M [10] and C isozymes [9,10]. How-
ever, it should be mentioned that this site has been proposed
to evolve of the duplicated phosphoenolpyruvate/ADP alloste-
ric site of the prokaryotic precursor, and to be composed of
residues from both halves of the same subunit [9]. In the case
of chimeric enzymes, this composition could also contribute to
the generation of new inhibitory properties, as observed with
ChiPFK-MC.
3.4. Activation by fructose-2,6-P2 and fructose-1,6-P2
The eﬀects of fructose-2,6-P2 and fructose-1,6-P2 on the chi-
meric enzymes were tested at concentrations of fructose-6-P
close to half saturation and inhibitory concentrations of
MgATP. As seen in Fig. 5A, activation by fructose-2,6-P2 of
each ChiPFK was virtually indistinguishable from that of the
native isozyme that provided the C-terminal half, with Kact val-
ues of 0.4 lM for ChiPFK-CM and HmPFK-M, and of 2 lM
for ChiPFK-MC and AtPFK-C. Thus, suggesting that the C-
terminal domain of mammalian PFK furnishes the fructose bis-phosphate allosteric site. Mutation of Arg-292 of rabbit PFK-
M led to propose that amino acids of both halves participate in
the binding site of fructose-2,6-P2 [8], as this compound slightly
activated the mutant which, nevertheless, showed high aﬃnity
for the eﬀector. This hypothesis is not favored by our results,
although they cannot exclude it either and, in any case, indicate
that the aﬃnity properties of the fructose bisphosphate binding
site are primarily contributed by amino acids of the C-terminus,
in which some residues have been found indispensable for acti-
vation by fructose-2,6-P2 [6–8]. In agreement with the above
data, ChiPFK-CM exhibited an activation curve for fructose-
1,6-P2, which was also practically coincident with that of
HmPFK-M (Kact = 1.0 lM) (Fig. 5B). Interestingly, although
AtPFK-C is insensitive to activation by fructose-1,6-P2,
ChiPFK-MC was markedly activated by this compound, show-
ing a Kact value of 9 lM, which is close to the reported [16] Kd
value (4 lM) of AtPFK-C for this metabolite. Therefore,
replacement of the N-terminal half of the latter isozyme by that
of HmPFK-M, restored the allosteric transition triggered by
binding of fructose-1,6-P2 at the fructose bisphosphate alloste-
ric site in the C-terminal half of AtPFK-C. These results further
evidence that diﬀerent signal transduction routes are involved
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mon site. Nevertheless, they do not allow to locate unambigu-
ously the region of AtPFK-C bearing the structural alteration
that prevents the allosteric transition elicited by fructose-1,6-
P2. Since ChiPFK-CM (containing the N-terminus of the C iso-
zyme) did not diﬀer from HmPFK-M in its activation by this
compound, we hypothesize that such an alteration aﬀects
mostly to the C-terminus of AtPFK-C, and that its negative ef-
fect is somehow overcome by interaction with the N-terminus
of the highly sensitive M isozyme.4. Conclusions
The results of this work show, ﬁrst, that it is possible to ex-
change the complete terminal halves of mammalian PFK iso-
zymes, producing chimeric enzymes fully active in vivo that
acquire the same quaternary structure than the native isozymes,
and that allow to analyze the contribution of each terminus to
the functional properties of speciﬁc binding sites. Secondly, our
data indicate that the N-terminal half is responsible for the
aﬃnity requirements of the catalytic site for fructose-6-P and
MgATP, whereas the C-terminal half is responsible for those
of the fructose-2,6-P2/fructose-1,6-P2 allosteric site. The latter
domain was also found crucial for the function of MgATP at
its inhibitory site. In the absence of a three-dimensional struc-
ture for a typical eukaryotic PFK, i.e. composed of duplicated
termini, these results strongly support the initial proposal [5]
that the N-terminal domain allocates the active site and that
the C-terminal provides the fructose bisphosphate binding site,
as suggested by the evolution of this enzyme. Additionally, this
approach provides evidence that the activating eﬀects of both
bisphosphates are mediated by distinct allosteric transitions.
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